呋喹替尼联合替雷利珠单抗二线治疗晚期结直肠癌患者应用效果及对血清CEA、CRP、IL-6水平影响  

The Efficacy of Second-line Treatment with the Combination of Fipronil and Tirelizumab in Patients with Advanced Colorectal Cancer and Its Impact on Serum CEA,CRP and IL-6 Levels

作　　者：赵海燕 孔莺 贺艳林 何瑞远 靳海涛 ZHAO Hai-yan;KONG Ying;HE Yan-lin;HE Rui-yuan;JIN Hai-tao(Department ofMedical Oncology,East Branch,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi,710089,China)

机构地区：[1]西安交通大学第一附属医院东院肿瘤内科,陕西西安710089

出　　处：《现代生物医学进展》2024年第23期4529-4531,共3页Progress in Modern Biomedicine

基　　金：陕西省自然科学基础研究计划项目(2020JM-369)。

摘　　要：目的:探讨呋喹替尼联合替雷利珠单抗二线治疗晚期结直肠癌患者应用效果及对血清CEA、CRP、IL-6水平影响。方法:选取2020.3~2023.3的82例晚期结直肠癌,分为观察组与对照组(41例)。患者一线治疗以FOLFOX方案为主,观察组采用呋喹替尼联合替雷利珠单抗二线治疗,对比相关指标。结果:观察组客观缓解率与疾病控制率较对照组高,CRP、IL-6、COX-2、CEA、CA199低于对照组(P<0.05);两组不良反应发生率对比无差异(P>0.05)。结论:呋喹替尼联合替雷利珠单抗二线治疗晚期结直肠癌疗效显著,可提升客观缓解率、疾病控制率,降低机体炎症反应、肿瘤标志物水平。Objective:To explore the efficacy of the combination of furoquinib and tirelizumab in second-line treatment of advanced colorectal cancer patients,as well as its impact on serum levels of Carcinoembryonic antigen(CEA),C-reactive protein(CRP),and interleukin-6(IL-6).Methods:82 cases of advanced colorectal cancer from 2020.3 to 2023.03 were selected and divided into observation group and control group(41 cases).The first-line treatment of patients was mainly FOLFOX regimen,and the observation group used second-line quintinib combined with furoquintinib and tirelibizumab,comparing relevant indicators.Results:The objective response rate and disease control rate in the observation group were higher than the control group,and CRP,IL-6,COX-2,CEA and CA199 were lower than the control group(P<0.05);there was no difference between the two groups(P>0.05).Conclusion:Furoquinitinib and tirellizumab are effective in the second-line treatment of advanced colorectal cancer,which can improve the objective response rate and disease control rate,and reduce the level of inflammatory response and tumor markers.

关 键 词：呋喹替尼 替雷利珠单抗 二线治疗 晚期结直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]